Compugen - Asset Resilience Ratio
Compugen (CGEN) has an Asset Resilience Ratio of 80.36% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Compugen for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2001–2024)
This chart shows how Compugen's Asset Resilience Ratio has changed over time. See net assets of Compugen for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Compugen's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CGEN stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA78.63 Million | 80.36% |
| Total Liquid Assets | ILA78.63 Million | 80.36% |
Asset Resilience Insights
- Very High Liquidity: Compugen maintains exceptional liquid asset reserves at 80.36% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Compugen Industry Peers by Asset Resilience Ratio
Compare Compugen's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 33.70% |
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392 |
Biotechnology | 11.64% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 2.21% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 82.25% |
Annual Asset Resilience Ratio for Compugen (2001–2024)
The table below shows the annual Asset Resilience Ratio data for Compugen.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 73.94% | ILA85.03 Million ≈ $227.95K |
ILA115.00 Million ≈ $308.30K |
+43.61pp |
| 2023-12-31 | 30.33% | ILA36.80 Million ≈ $98.65K |
ILA121.33 Million ≈ $325.29K |
-46.43pp |
| 2022-12-31 | 76.76% | ILA72.29 Million ≈ $193.80K |
ILA94.18 Million ≈ $252.48K |
-5.90pp |
| 2021-12-31 | 82.66% | ILA109.25 Million ≈ $292.89K |
ILA132.16 Million ≈ $354.32K |
-1.65pp |
| 2020-12-31 | 84.32% | ILA116.62 Million ≈ $312.66K |
ILA138.32 Million ≈ $370.82K |
+21.00pp |
| 2019-12-31 | 63.31% | ILA34.04 Million ≈ $91.26K |
ILA53.76 Million ≈ $144.14K |
-10.41pp |
| 2018-12-31 | 73.73% | ILA39.21 Million ≈ $105.12K |
ILA53.18 Million ≈ $142.57K |
+63.62pp |
| 2017-12-31 | 10.11% | ILA3.92 Million ≈ $10.50K |
ILA38.75 Million ≈ $103.88K |
-61.33pp |
| 2016-12-31 | 71.44% | ILA50.83 Million ≈ $136.26K |
ILA71.14 Million ≈ $190.72K |
+71.02pp |
| 2015-12-31 | 0.43% | ILA426.00K ≈ $1.14K |
ILA99.31 Million ≈ $266.24K |
-0.49pp |
| 2014-12-31 | 0.92% | ILA1.05 Million ≈ $2.83K |
ILA114.84 Million ≈ $307.90K |
-7.13pp |
| 2013-12-31 | 8.05% | ILA4.57 Million ≈ $12.24K |
ILA56.71 Million ≈ $152.04K |
-9.92pp |
| 2012-12-31 | 17.97% | ILA5.20 Million ≈ $13.93K |
ILA28.91 Million ≈ $77.50K |
-38.85pp |
| 2011-12-31 | 56.82% | ILA16.52 Million ≈ $44.30K |
ILA29.08 Million ≈ $77.97K |
+16.99pp |
| 2010-12-31 | 39.84% | ILA14.52 Million ≈ $38.94K |
ILA36.46 Million ≈ $97.74K |
-1.70pp |
| 2008-12-31 | 41.53% | ILA5.92 Million ≈ $15.86K |
ILA14.24 Million ≈ $38.19K |
-22.09pp |
| 2007-12-31 | 63.62% | ILA13.78 Million ≈ $36.95K |
ILA21.67 Million ≈ $58.09K |
+1.55pp |
| 2006-12-31 | 62.07% | ILA19.15 Million ≈ $51.35K |
ILA30.86 Million ≈ $82.72K |
-9.79pp |
| 2005-12-31 | 71.86% | ILA30.26 Million ≈ $81.12K |
ILA42.11 Million ≈ $112.88K |
+42.58pp |
| 2004-12-31 | 29.28% | ILA16.21 Million ≈ $43.45K |
ILA55.35 Million ≈ $148.40K |
+16.25pp |
| 2003-12-31 | 13.03% | ILA8.80 Million ≈ $23.58K |
ILA67.53 Million ≈ $181.03K |
-3.69pp |
| 2002-12-31 | 16.72% | ILA12.92 Million ≈ $34.63K |
ILA77.26 Million ≈ $207.12K |
+6.13pp |
| 2001-12-31 | 10.59% | ILA9.24 Million ≈ $24.77K |
ILA87.29 Million ≈ $234.02K |
-- |
About Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical tria… Read more